Spectrum Terminates Its 648-Patient Poziotinib Exon 20 Phase 2 — A Business Call, Not Safety

Prognyx Competitive Intelligence Briefing — 15 June 2026

What Happened

The TERMINATED status appears in the ClinicalTrials.gov record for NCT03318939, last updated 2026-06-12. ^[1] The study is Spectrum Pharmaceuticals' Phase 2 investigation of Poziotinib in NSCLC patients harboring EGFR or HER2 Exon 20 insertion mutations. ^[1] The stated termination reason is unambiguous: "Strategic business decision (unrelated to safety)." ^[1]

The trial's operational history warrants close reading before drawing conclusions:

• Design: Open-label, multi-center Phase 2; seven cohorts (expanded from the initial design via two protocol amendments — Amendment 1 added Cohorts 3–4; Amendment 2 added Cohorts 5–7). ^[1]
• Enrollment: Planned cap of 603 participants; actual enrollment reached 648. ^[1]
• Primary endpoint: Objective Response Rate (ORR) only. ^[1]
• Active run: Study opened 2017-10-11; primary completion recorded 2023-04-03 — a ~5.5-year operational lifespan. ^[1]
• Intervention: Poziotinib, developed by Spectrum Pharmaceuticals, Inc. ^[1]

Three facts from the registry record are structurally important. First, enrollment (648) exceeded the planned cap (603), ruling out early closure driven by poor accrual. ^[1] Second, primary completion — the milestone marking the end of primary efficacy data collection — was recorded in April 2023, ahead of the 2026-06-12 record update; the registry does not specify when the termination decision itself was formally taken. ^[1] Third, the safety carve-out is explicit and unhedged. ^[1]

Unconfirmed items — referenced throughout this briefing: Published or presented ORR results from NCT03318939; whether an NDA or sNDA for Poziotinib in this indication was filed, withdrawn, or declined; Spectrum's current corporate structure, filing status, and pipeline beyond NCT03318939; and competitive landscape data for other agents in the Exon 20 space. None of these are established by any source available to Prognyx as of 15 June 2026. Subsequent references to these gaps do not repeat this caveat in full.

Why It Matters

A termination of this architecture is not routine program closure. Three structural features distinguish it.

1. Primary-endpoint data were already in hand.

Primary completion (April 2023) means primary-endpoint data collection was complete before the record was updated to TERMINATED. ^[1] The decision to terminate is therefore an administrative close on a completed primary-endpoint dataset — not a mid-course exit. The operative question is what the ORR data showed, and whether Spectrum evaluated and declined to pursue a regulatory submission. Both are unconfirmed (see above).

2. Safety is explicitly cleared.

The termination language leaves no interpretive room: not a tolerability failure, not a regulatory hold — a business call. ^[1] That explicit carve-out is notable in a field where most program terminations are buried in tolerability or futility language.

3. The regulatory file is an open question.

Spectrum's stated rationale beyond the "strategic business decision" language ^[1] — and any NDA or sNDA filing history — are unconfirmed. A seven-cohort, 648-patient program spanning 5.5 years ^[1] has been formally closed without a regulatory submission visible in public sources. Resolving that unknown is the first analytical step for any team tracking this indication.

Who Is Exposed / Who Gained

This termination removes Spectrum's only publicly registered clinical program in EGFR/HER2 Exon 20 NSCLC. ^[1] The dossier covers only NCT03318939 and does not establish Spectrum's broader pipeline; no other Spectrum Exon 20 program is confirmed in the available record. The seven-cohort architecture — spanning treatment-naïve and previously treated populations across two distinct mutation subtypes — reflected a broad label aspiration. ^[1] That aspiration is now archived.

Prognyx assesses this as a material alteration of Spectrum's clinical position in this indication. The competitive landscape — approval status and label scope of other agents in the Exon 20 space — cannot be sourced from this dossier, and Prognyx does not assert competitor exposure or competitive gain without a primary-source URL.

One structural observation is defensible from the confirmed record: a seven-cohort, 648-patient ^[1] Phase 2 with primary-endpoint data complete ^[1] and an explicitly safety-cleared termination ^[1] now sits unattached to any active registered program. Whether that dataset has licensing, partnership, or transactional value depends on ORR results and regulatory history — both unconfirmed (see above).

What to Watch Next

Three intelligence items would materially change the interpretation of this termination. None carry confirmed future dates as of this briefing.

1. Spectrum's corporate and filing status — confirm this first.

Before monitoring any formal disclosures, establish whether Spectrum remains an independent, active organization. If Spectrum remains an independent SEC registrant, monitor EDGAR for filings dated after the 2026-06-12 record update; ^[1] if it has been acquired or restructured, monitor the successor or acquirer's filings instead. This corporate-status check is prerequisite to any disclosure watch or BD outreach.

2. Publication or congress presentation of ORR data from NCT03318939.

Primary completion was April 2023. ^[1] If Spectrum has presented or intends to present results at ASCO, WCLC, or in a peer-reviewed journal, those data would supply the efficacy context the registry record does not provide. No such presentation is confirmed in public sources as of this briefing.

3. FDA regulatory history for Poziotinib in NSCLC Exon 20.

Whether an NDA or sNDA was filed, received a Complete Response Letter, or was withdrawn is unconfirmed — and is the single highest-leverage unknown: a prior regulatory rejection would reframe the "strategic decision" as regulatory reality. Monitor FDA action letters and CDER databases accordingly.

The Now-What: Strategic Options on the Table

For a BD director or R&D VP tracking the Exon 20 space, three actions are defensible from confirmed public information alone.

Option 1 — Close the data gap before modeling competitive impact.

The ORR primary endpoint was measured; primary completion was logged April 2023. ^[1] A structured literature search for NCT03318939 publications or congress abstracts costs nothing and resolves the most material efficacy unknown before any resource commitment. If results have been published, the efficacy read on Poziotinib in Exon 20 is already in the open literature.

Option 2 — Verify Spectrum's corporate status before assessing dataset value.

A seven-cohort, 648-patient ^[1] Phase 2 with a defined primary endpoint ^[1] and an explicitly safety-cleared termination ^[1] has informational and potentially transactional value. The appropriate near-term step is a corporate-status check via public filings — confirming whether Spectrum remains an independent, active organization — before any BD approach or dataset valuation.

Option 3 — Set a regulatory and pipeline watch.

The TERMINATED status in the registry, last updated 2026-06-12, ^[1] indicates the administrative machinery has already moved. Automated alerts on ClinicalTrials.gov for any new Poziotinib- or Exon 20-related registrations, and CDER monitoring for Poziotinib regulatory history, represent the lowest-cost ongoing posture. No timeline for further disclosure can be confirmed from available sources.

Verdict: Primary-endpoint data in hand, safety explicitly cleared, no visible regulatory submission — the confirmed structural read is unusually clean for a program of this scale. ^[1] Three unknowns determine the strategic weight: ORR results, FDA filing history, and Spectrum's current corporate and pipeline status. Resolve those three — in that order — before committing resources. Threat level for others in the Exon 20 indication: unquantifiable until those data surface.